PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Diagnostic Testing for Pathogen Detection Triggers Significant Demand for PCR Reagents Finds Frost & Sullivan - Intensifying price pressures can dampen market enthusiasm and must be dealt with to retain competitive edge - DrugDiscovery.frost.com / Frost.com
Diagnostic Testing for Pathogen Detection Triggers Significant Demand for PCR Reagents Finds Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2011/07/20 - Intensifying price pressures can dampen market enthusiasm and must be dealt with to retain competitive edge - DrugDiscovery.frost.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Novel next-generation polymerase chain reaction (PCR) reagents engineered for clinical diagnostics have rapidly increased the scope and usage of PCR reagents for pathogen and disease detection.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), European PCR Reagent Market for Research Applications and Clinical Diagnostics, finds that the market earned revenue of $883 million in 2010 and estimates this to reach $1600.1 million in 2017. The research covers PCR reagents being used and supplied for clinical diagnostics, research application and applied testing sectors.

Significant market growth, since 2007, can be attributed to the patent expiry of Taq polymerase. With its expiry, PCR reagents have been made available for more common use, increasing consumption levels.

"There is rising demand for PCR reagents in diagnostic testing for pathogen detection," notes Frost & Sullivan Research Analyst Divyaa Ravishankar. "Innovative product features are, moreover, expanding the customer base, resulting in higher revenue generation."

Clinicians are utilising PCR to conduct routine medical diagnostic tests and reveal important information such as the identification of biomarkers. This may reveal the early signs of development of cancer, tumours, heart disease and many more.

In the area of life sciences research, PCR reagents are being deployed in human disease research, genetic analysis, pharmaceutical drug discovery development, pharmacogenomics and toxicogenomics. Next-generation PCR enzymes have been engineered to suit the specific requirements of these varied applications.

Intensifying price pressures due to increased competition presents a major challenge to market expansion. The cost of the PCR reagents is a major concern, especially when research is being carried out in an academic laboratory. Due to the cost issue, researchers prefer the use of home-brewed reagents rather than purchasing reagents that are at the high end.

The requirement of licenses is stifling the entry of new entrants into in vitro diagnostics. This situation threatens to dampen revenue growth.

"The key technologies are patent protected, which prevents the free growth of the market," explains Ravishankar. "As the Tier 1 participants have already acquired patents, new participants have to be creative to expand their usage in terms of improved speed, processing and robustness, resulting in consistency of high amplification efficiency required for accurate relative quantification, regardless of amplicon length or complexity."

Companies that fail to address the issue of pricing at the appropriate time, stand to lose their competitive advantage. Many companies have entered into alliances with thermal cycler manufacturers and are using this strategy to market their brands.

If you are interested in more information on this study, please send an email with your contact details to Janique Morvan, Corporate Communications, at janique.morvan[.]frost.com.

European PCR Reagent Market for Research Applications and Clinical Diagnostics is part of the Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: European HIV/AIDS and Hepatitis B/C Molecular Diagnostics Market and European Point of Care (POC) Infectious Disease Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

European PCR Reagent Market for Research Applications and Clinical Diagnostics / M6DD

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Diagnostic Testing for Pathogen Detection Triggers Significant Demand for PCR Reagents Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Janique Morvan 
+33 (0)1 42 81 20 37 janique.morvan[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)